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Nonrandom chromosomal translocations
associated with soft tissue sarcomas,
similar to those found in hematological
malignancies, have drawn much atten-
tion. The most striking feature of these
genetic aberrations is the tight association
of a particular translocation breakpoint to
a certain tumor type. The first glimpse at
the underlying molecular mechanism of
human soft tissue sarcomas came from
the cloning of the t(11;22)(q24;q12)
translocation breakpoint gene associated
with Ewing’s sarcoma (Delattre et al.,
1992). Sequence analysis has revealed a
gene fusion event of the EWS gene on
chromosome 22q12 to the DNA binding
domain of the transcription factor FLI1
located on chromosome 11q24. Similar
fusion products have subsequently been
isolated from various other soft tissue
tumors, including desmoplastic small
round cell tumor (DSRCT). Many of these
translocations involve the fusion of the
EWS gene and members of the growing
family of ETS transcription factors
(Arvand and Denny, 2001).
It is clear that these tumor-associated
fusion products are bona fide oncopro-
teins. For example, it has been shown that
some of these chimeric molecules can
promote anchorage-independent growth
and enhance tumorigenicity in animals.
Furthermore, site-directed mutagenesis
of the EWS and ETS coding sequences
and antisense oligonucleotide-based
experiments strongly suggest that
EWS/ETS fusion products are required
for the initiation and perhaps the mainte-
nance of malignant phenotypes.
Intuitively, these chimeric transcrip-
tion factors are expected to regulate the
transactivation of genes important for
cell growth and differentiation. In
DSRCT, it has been shown previously
that EWS-WT1 increased transcription
of interleukin (IL)-2/15 receptor-β and
PDGF-A (Lee et al., 1997; Wong et al.,
2002). Palmer and colleagues (Palmer et
al., 2002) now add an additional target to
the mix. By expressing the EWS-
WT1 fusion gene under a tetracycline-
repressible promoter in U2OS osteosar-
coma, they have isolated a gene,
BAIAP3 (Brain-specific angiogenesis
inhibitor 1 [BAI1] associated protein 3)
(Shiratsuchi et al., 1998), which is up-
regulated by more than 100-fold (Figure
1). Importantly, BAIAP3-transcripts could
also be detected in tumor but not stromal
cells of DSRCT specimens, supporting a
role of BAIAP3 in tumor promotion. In
addition, ectopic expression of BAIAP3
in a melanoma cell line (MC) enhanced
cell proliferation under low serum condi-
tions, promoted anchorage-independent
growth, and augmented tumor formation
in animals.
Interestingly, BAIAP3 is a member of
a family of proteins whose founding
member, the C. elegans protein Unc13,
has been implicated in the regulation of
exocytosis (Brose et al., 2000; Koch et
al., 2000). Indeed, it has been demon-
strated that Munc13-1 (the mammalian
homolog of Unc13) is directly involved in
a process called priming of large dense-
core vesicles in chromaffin cells (Ashery
et al., 2000; Brose et al., 2000).
Fusion of large dense-core vesicles
(and other vesicles such as synaptic vesi-
cles at the neuronal synapse) is a
multistep, highly regulated process culmi-
nating in the assembly of SNARE protein
complexes that drive membrane fusion
and release of vesicle contents into the
extracellular space. Morphological dock-
ing of the vesicles to the plasma mem-
brane is followed by a series of events,
one of which is called priming, before
Ca2+-triggered exocytosis takes place.
Munc13-1 is an essential player in the
process of priming (Ashery et al., 2000;
Brose et al., 2000). Largely based on the
homology to Munc13-1, it has been sug-
gested that members of this family of pro-
teins, such as BAIAP3, play important
roles in regulated exocytosis (Brose et al.,
2000; Koch et al., 2000; Palmer et al.,
2002; Shiratsuchi et al., 1998).
Perhaps it should come as no sur-
prise that exocytosis and tumor growth
might be linked. There is ample evidence
in the past demonstrating that increased
production and resulting secretion of cer-
tain growth factors such as PDGF, FGF,
and others can result in oncogenic trans-
formation. What is exciting about the
work of Haber and colleagues is that it
opens the possibility that modulation of
exocytosis per se might play a role in
tumor development.
It is interesting to speculate how
BAIAP3 overexpression, by virtue of
modulating secretion, could transform a
cell. One attractive model is that since
EWS-WT1 has previously been shown to
increase the expression of several
growth-promoting soluble factors, includ-
ing PDGF-A and IGF-1, the simultane-
ous upregulation of BAIAP3 will lead to
their overall increased secretion to the
extracellular compartment. On the other
hand, the activity of BAIAP3 is likely sub-
jected to modulation itself. In this model,
overexpression of BAIAP3 could make
secretion of growth-enhancing factors
independent from an otherwise neces-
sary, exocytosis-promoting signal. In
DSRCT, these mitogenic factors can
potentially act in either an autocrine or a
paracrine fashion. The dense stroma,
which is characteristic of DSRCT, is cer-
tainly consistent with a role of paracrine
stimulation in tumor growth.
The literature is filled with examples
of tumors where growth factors and
cytokines play an important role in tumor
progression (Aaronson, 1991). For exam-
ple, PDGF and its receptors are coex-
pressed in a high fraction of sarcomas
and malignant gliomas. The existence of
a functional autocrine loop in these cases
has been implicated in promoting tumor
proliferation. In addition, increases in the
production of soluble factors, such as
EGF, PDGF, IL-1, and VEGFs, can act in
a paracrine fashion to modulate tumor
growth and metastasis by acting on stro-
mal cells and stimulating the formation of
new vasculature (angiogenesis) or lymph
vessels (lymphangiogenesis).
Usually, this is associated with
increased transcription and expression
of these soluble factors. Consequently,
so far, little if any attention has been paid
to a possible role of regulation of the exo-
cytic machinery in the pathogenic devel-
opment of these tumors. Clearly, the data
provided by Palmer et al. (2002) provide
a strong impetus to revisit these and sim-
ilar cases with an increased focus on
exocytosis.
A putative link between exocytosis and tumor development
Desmoplastic small round cell tumor (DSRCT) is characterized by a t(11;22)(p13;q12) translocation breakpoint. In this
issue of Cancer Cell, Palmer et al. (2002) now show that the resulting EWS-WT1 gene-fusion product leads to overexpres-
sion of BAIAP3, a protein implicated in regulated exocytosis.
428 CANCER CELL : DECEMBER 2002
P R E V I E W S
The link of BAIAP3 to tumorigenesis
also raises the possibility that other pro-
teins involved in exocytosis could play a
role in cancer progression. Growth factor
receptors have become attractive targets
for cancer therapy. For instance, her-
ceptin, which is an antibody against
HER2/neu, has become an important
tool in the treatment of breast cancer.The
inhibition of signaling molecules, such as
kinases, has become an important strate-
gy in cancer therapy. As an example, the
kinase inhibitor STI571 (Glivec) aimed at
the fusion product Bcr-Abl has been
shown to be highly effective in the treat-
ment of chronic myelogenous leukemia.
Similarly, BAIAP3—and in the future, per-
haps other proteins involved in exocyto-
sis—has now become a potential
therapeutic target. The importance of
new avenues of treating cancer by dis-
covering new pathways of tumor progres-
sion cannot be overestimated.
The study of Palmer et al. represents
the first—albeit still tentative—link
between cancer and exocytosis. While
much remains to be learned about the
mechanism and the precise role of
BAIAP3 in tumorigenesis, the publication
of Haber and colleagues (Palmer et al.,
2002) is the first page of a new chapter in
cancer research.
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Figure 1. Possible mechanism for stimulation of tumor progression by transcriptional activation of BAIAP3 
Translocation of the N-terminal domain of the Ewing’s Sarcoma (EWS) gene on to the C-terminal domain of the Wilms’ Tumor 1 (WT1) gene results
in the expression of an EWS-WT1 fusion protein. EWS-WT1 has now been shown to transactivate BAIAP3. BAIAP3, similar to a homologous protein
Munc13-1, might be involved in the regulation of exocytosis.  One possibility is that, like Munc13-1, BAIAP3 might stimulate a process called prim-
ing. Priming has been reported to be a necessary step in the secretion of vesicular contents from large dense core vesicles. Alternatively, BAIAP3
might influence other steps in the exocytic pathway. The increased secretion of growth factors or cytokines could then stimulate tumor progres-
sion of desmoplastic small round cell tumor (DSRCT) in an autocrine and/or paracrine fashion.
